Theralase(R) Extends Warrants

Rhea-AI Summary

Theralase Technologies, a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated molecules for cancer and pathogen treatment, announced plans to extend the expiry date of 1,000,000 share purchase warrants. The warrants, originally issued on November 17, 2022, through a private placement, will be extended from November 17, 2024, to November 17, 2027. The warrants remain exercisable at $0.35 per share, with all other terms unchanged. The extension requires TSX Venture Exchange approval.

TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase^® Technologies Inc. ("Theralase^®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,000,000 share purchase warrants ("Warrants") from November 17, 2024 to November 17, 2027.

The Warrants were issued on November 17, 2022, pursuant to a private placement involving the issuance of 1,000,000 units of the Company. The Warrants are exercisable at $0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange.

About Theralase® Technologies Inc.:

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedarplus.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's small molecules and their drug formulations, preclinical research, clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all, the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.

Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.

For More Information:

1.866.THE.LASE (843-5273)
416.699.LASE (5273)

www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer
X 224
khachey@theralase.com

SOURCE: Theralase Technologies, Inc.

View the original press release on accesswire.com

FAQ

What is the new expiry date for Theralase (TLTFF) warrants issued in November 2022?

The warrants' expiry date will be extended from November 17, 2024, to November 17, 2027, subject to TSX Venture Exchange approval.

What is the exercise price of Theralase (TLTFF) warrants being extended?

The warrants are exercisable at $0.35 per share.

How many warrants are affected by Theralase's (TLTFF) warrant extension?

The warrant extension affects 1,000,000 share purchase warrants that were issued on November 17, 2022.